treatment of various skin disorders.
  • Dermomax® is a corticosteroid used topically for its glucocorticoid activity in the treatment of various skin disorders.

Dermomax® cream contains:

  • Clobetasol propionate                    0.05% w/w.

Dermomax® is of particular value when used in short courses for the treatment of:

  • Psoriasis ( excluding widespread plaque Psoriasis).  
  • Recalcitrant eczemas.   
  • Lichen Planus. 
  • Discoid lupus erythematosus.
  • And other conditions which do not respond satisfactorily to less active steroids.

Dermomax® is contraindicated in:

  • Patients with hypersensitivity to Clobetasol propionate.
  • Treatment of simple skin diseases, especially in face and genitals.
  • Rosacea, acne vulgaris, peri oral dermatitis, primary cutaneous viral infections as Herpes simplex and chickenpox.
  • The treatment of primarily infected skin lesions caused by infection with fungi (e.g : Candidiasis,Tinea ), or bacteria (e.g : Impetigo) and perianal and genital Pruritus.
  • Dermomax® is not used to treat Dermatoses in children under one year of age, including dermatitis and napkin eruptions. 
  • Clobetasol propionate is well tolerated, but if signs of hypersensitivity occur, application should be stopped immediately.
  • As with other topical corticosteroids, prolonged use of large amounts or treatment of extensive areas can result in sufficient systemic absorption to produce the features of hypercorticism.
  • Prolonged and intensive use of Clobetasol propionate may cause atrophic changes, such as :Striae, thinning of the skin, and dilatation of the superficial blood vessels particularly when occlusive dressings are used or where skin folds are involved.
  • Apply a thin film of Dermomax® sparingly to the affected area once or twice daily until improvement occurs and therapy should be discontinued when control is achieved.
  • If no improvement is seen within two to four weeks, reassessment of the diagnosis, or referral may be necessary.
  • If continues steroid treatment is necessary, less potent preparations should be used.
  • In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of Dermomax® can be enhanced, if necessary by overnight occluding the treatment area with polythene film, and thereafter the improvement can be maintained by application without occlusion.
  • Long term continuous topical therapy of Dermomax® should be avoided where possible, particularly in infants and children, as adrenal suppression can occur.
  • If possible, do not use Dermomax® for more than five days on the face and avoid occlusion.
  • Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected.
  • No approved findings for abnormalities to human fetus, however Dermomax® should not be used extensively in pregnancy.
  • Dermomax® cream: tube of 20 gm.
  • Store at a temperature not exceeding 25°C.